Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Zahrieh

Showing results (11-20 of 88) with videos related to

Pageof 9
Sort By:
Blood Cells, Molecules & Diseases|March 4, 2014
Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-upDeborah Elstein, Andrew H Haims, David Zahrieh, et al.
The Journal of Clinical Investigation|May 20, 2005
Ferroportin1 is required for normal iron cycling in zebrafishPaula G Fraenkel, David Traver, Adriana Donovan, et al.
The Journal of Clinical Investigation|June 21, 2005
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cellsGüllü Görgün, Tobias A W Holderried, David Zahrieh, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 3, 2025
Was it Worth It? Response Data from >650 United States and International Participants in Chemoprevention TrialsDavid Zahrieh, Carrie A Strand, Paul J Limburg, et al.
Cancers|March 10, 2022
Temporal, Location- and Symptom-Specific Likelihood of Patient-Reported Sensory Symptoms Related to Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in Patients Receiving Oxaliplatin for Three MonthsDavid Zahrieh, Daniel Satele, Ellen M Lavoie Smith, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 26, 2018
Nasal vestibulitis: an under-recognized and under-treated side effect of cancer treatment?Elizabeth Cathcart-Rake, Deanne Smith, David Zahrieh, et al.
Blood Cells, Molecules & Diseases|May 4, 2011
Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reductionDeborah Elstein, A Joseph Foldes, David Zahrieh, et al.
Transfusion|April 19, 2003
Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitutionAbba Zubair, David Zahrieh, Heather Daley, et al.
Biotechniques|November 25, 2003
Zebrafish sperm cryopreservation with N,N-dimethylacetamideJohn P Morris, Stephane Berghmans, David Zahrieh, et al.
Transplantation|July 23, 2002
Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantationThomas S Lin, David Zahrieh, Edie Weller, et al.
Pageof 9

Showing results (11-20 of 88) with videos related to

Sort By:
Pageof 9
Blood Cells, Molecules & Diseases|March 4, 2014
Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-upDeborah Elstein, Andrew H Haims, David Zahrieh, et al.
The Journal of Clinical Investigation|May 20, 2005
Ferroportin1 is required for normal iron cycling in zebrafishPaula G Fraenkel, David Traver, Adriana Donovan, et al.
The Journal of Clinical Investigation|June 21, 2005
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cellsGüllü Görgün, Tobias A W Holderried, David Zahrieh, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 3, 2025
Was it Worth It? Response Data from >650 United States and International Participants in Chemoprevention TrialsDavid Zahrieh, Carrie A Strand, Paul J Limburg, et al.
Cancers|March 10, 2022
Temporal, Location- and Symptom-Specific Likelihood of Patient-Reported Sensory Symptoms Related to Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in Patients Receiving Oxaliplatin for Three MonthsDavid Zahrieh, Daniel Satele, Ellen M Lavoie Smith, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 26, 2018
Nasal vestibulitis: an under-recognized and under-treated side effect of cancer treatment?Elizabeth Cathcart-Rake, Deanne Smith, David Zahrieh, et al.
Blood Cells, Molecules & Diseases|May 4, 2011
Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reductionDeborah Elstein, A Joseph Foldes, David Zahrieh, et al.
Transfusion|April 19, 2003
Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitutionAbba Zubair, David Zahrieh, Heather Daley, et al.
Biotechniques|November 25, 2003
Zebrafish sperm cryopreservation with N,N-dimethylacetamideJohn P Morris, Stephane Berghmans, David Zahrieh, et al.
Transplantation|July 23, 2002
Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantationThomas S Lin, David Zahrieh, Edie Weller, et al.
Pageof 9